Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Director departure
CC transcript
Quarterly results
|
|
Aegerion Pharmaceuticals, Inc. (AEGR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/29/2016 |
8-K
| Quarterly results |
| 11/07/2016 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/03/2016 |
8-K
| Form 8-K - Current report |
| 10/24/2016 |
8-K
| Form 8-K - Current report |
| 10/20/2016 |
8-K
| Other Events |
| 10/03/2016 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/09/2016 |
8-K
| Quarterly results |
| 08/08/2016 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/20/2016 |
8-K
| Form 8-K - Current report |
| 07/05/2016 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/15/2016 |
8-K
| Form 8-K - Current report |
| 06/01/2016 |
8-K
| Form 8-K - Current report |
| 05/16/2016 |
8-K
| Quarterly results |
| 05/12/2016 |
8-K
| Form 8-K - Current report |
| 03/22/2016 |
8-K
| Form 8-K - Current report |
| 03/10/2016 |
8-K
| Form 8-K - Current report |
| 02/29/2016 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/25/2016 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 02/11/2016 |
8-K
| Form 8-K - Current report |
| 02/03/2016 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/11/2016 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 12/07/2015 |
8-K
| Other Events |
| 11/10/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/09/2015 |
8-K
| Quarterly results |
| 09/23/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Amended and Restated Inducement Award Stock Option Plan",
"Donald K. Stern, Esq. Appointed to Aegerion Pharmaceuticals' Board of Directors Cambridge, MA, September 18, 2015 - Aegerion Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Donald K. Stern, Esq., to its Board of Directors, effective immediately. Mr. Stern will serve as a Class III director and will be up for reelection to the Board of Directors in 2016. David Scheer, Chairman of the Board of Aegerion, said, “One of Aegerion's fundamental values is a culture focused on compliance in all disciplines. The addition of Don to Aegerion's Board of Directors reinforces our strong commitment to maintaining a high ethical standard and robust compliance program. W..." |
|
| 08/11/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/05/2015 |
8-K
| Quarterly results |
| 07/29/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/29/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Aegerion Pharmaceuticals Appoints Gregory Perry as Chief Financial Officer Cambridge, MA, June 25, 2015 - Aegerion Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced the appointment of Gregory D. Perry as chief financial officer, effective July 6, 2015. Mr. Perry replaces David Aubuchon, interim chief financial officer, who will continue in his role as chief accounting officer of Aegerion. Marc Beer, Chief Executive Officer of Aegerion said, “Greg brings strong financial acumen, global biotech operational expertise and leadership capabilities to Aegerion during an important time in the Company's evolution. We look forward to his contributions as a member of th..." |
|
| 05/14/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/04/2015 |
8-K
| Quarterly results |
| 04/09/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Jorge Plutzky, M.D., Appointed to Aegerion Pharmaceuticals' Board of Directors Cambridge, MA, April 9, 2015— Aegerion Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Jorge Plutzky, M.D., to its Board of Directors, effective immediately. Dr. Plutzky will serve as a Class I director and will be up for reelection to the Board of Directors in 2017. Dr. Plutzky will serve on the Nominating and Corporate Governance Committee of the Board. Dr. Plutzky was appointed to the Board as an independent director pursuant to a Nomination and Standstill Agreement with Sarissa Capital Management LP and related funds. David Scheer, Chairman of the Board of Aegerion said, ..." |
|
| 03/31/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Nomination and Standstill Agreement, among Aegerion Pharmaceuticals, Inc., Sarissa Capital Management LP, Sarissa Capital Domestic Fund LP, Sarissa Capital Offshore Master Fund LP, Sarissa Capital Fund GP LP and Sarissa Capital Offshore Fund GP LLC",
"Nomination and Standstill Agreement, among Aegerion Pharmaceuticals, Inc., Sarissa Capital Management LP, Sarissa Capital Domestic Fund LP, Sarissa Capital Offshore Master Fund LP, Sarissa Capital Fund GP LP and Sarissa Capital Offshore Fund GP LLC" |
|
| 02/26/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
|
|
|